Multibagger Pharma Stock Rises Nearly 3 Per Cent After US FDA Observations on Telangana Facility
Multibagger Pharma Stock Rises Nearly 3 Per Cent After US FDA Observations on Telangana Facility

Multibagger Pharma Stock Rises Nearly 3 Per Cent After US FDA Observations on Telangana Facility

The inspection, conducted between December 9 and December 17, 2024, resulted in two procedural observations from the US FDA.

Manoj Reddy Sama Article rating: 4.3

The facility in question, Unit-V, is an active pharmaceutical ingredient (API) manufacturing site operated by Apitoria Pharma Private Ltd, a wholly owned subsidiary of Aurobindo Pharma, located in Pashamylaram Village, Telangana.

 

FIIs and DIIs Increase Stake: Small-cap Pharma Company Reports Over 11 Times Jump in Net Profit
FIIs and DIIs Increase Stake: Small-cap Pharma Company Reports Over 11 Times Jump in Net Profit

FIIs and DIIs Increase Stake: Small-cap Pharma Company Reports Over 11 Times Jump in Net Profit

The company reported an impressive over 11 times growth in net profit for the second quarter of FY25, with Profit After Tax (PAT) reaching Rs 17.94 crore compared to Rs 1.61 crore in the same period last year.

Manoj Reddy Sama Article rating: 4.0

Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) significantly increased their holdings in Shilpa Medicare during Q2 of FY25.

Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high
Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high

Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high

The shares of the company saw a spurt in volume by more than 2 times.

Kiran Shroff Article rating: 5.0

The stock gave multibagger returns of 200 per cent in 1 year, 850 per cent in 3 years and a whopping 3,000 per cent in 5 years.

Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!
Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!

Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!

With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence

Pushkar Shinde Article rating: 5.0

With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence

Vijay Kedia & Mukul Agrawal’s Portfolio Multibagger Pharma Stock Falls Over 14 Per Cent In Past 1 Hour; Here’s Why
Vijay Kedia & Mukul Agrawal’s Portfolio Multibagger Pharma Stock Falls Over 14 Per Cent In Past 1 Hour; Here’s Why

Vijay Kedia & Mukul Agrawal’s Portfolio Multibagger Pharma Stock Falls Over 14 Per Cent In Past 1 Hour; Here’s Why

The company has a market cap of over Rs 17,000 crore with a PE of 55x, an ROE of 27 per cent and an ROCE of 33 per cent.

Kiran Shroff Article rating: 4.5

The stock gave multibagger returns of 250 per cent in 1 year, 720 per cent in 3 years and a whopping 2,700 per cent in 5 years.

Multibagger Pharma Stock Hit 52-Week High As Board Announces Stock Split From Rs 5 to Rs 2 and Stellar Quarterly Results (Q2FY25) and Half-Yearly Results (H1FY25)
Multibagger Pharma Stock Hit 52-Week High As Board Announces Stock Split From Rs 5 to Rs 2 and Stellar Quarterly Results (Q2FY25) and Half-Yearly Results (H1FY25)

Multibagger Pharma Stock Hit 52-Week High As Board Announces Stock Split From Rs 5 to Rs 2 and Stellar Quarterly Results (Q2FY25) and Half-Yearly Results (H1FY25)

The stock is up by 85 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of 1,895 per cent in 5 years.

Kiran Shroff Article rating: 3.9

The stock is up by 85 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of 1,895 per cent in 5 years.

Multibagger Pharma Stock To Keep Under Radar As Board Likely To Announce Stock Split
Multibagger Pharma Stock To Keep Under Radar As Board Likely To Announce Stock Split

Multibagger Pharma Stock To Keep Under Radar As Board Likely To Announce Stock Split

The stock is up by 75 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of over 1,800 per cent in 5 years.

Kiran Shroff Article rating: 4.1

The stock is up by 75 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of over 1,800 per cent in 5 years.

Pharma Penny Stock At Rs 65 Enters Into An Mou With Vaibhav Kashinath Chaudhari & Mistycube Analytics To Enter French West African Market
Pharma Penny Stock At Rs 65 Enters Into An Mou With Vaibhav Kashinath Chaudhari & Mistycube Analytics To Enter French West African Market

Pharma Penny Stock At Rs 65 Enters Into An Mou With Vaibhav Kashinath Chaudhari & Mistycube Analytics To Enter French West African Market

The company has a market cap of Rs 76 crore and as of September 27, 2024, the stock is trading at Rs 65 per share on NSE.

Kiran Shroff Article rating: 4.3

The company has a market cap of Rs 76 crore and as of September 27, 2024, the stock is trading at Rs 65 per share on NSE.  

RSS
1234

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR